Head and neck cancers arising from the upper aerodigestive tract are the sixth leading cause of cancer-related mortality, with over 550,000 new cases per year
worldwide. Though it continues to be prevalent, the etiology of oropharyngeal cancer (OPC; cancer of the tonsil and base of tongue) has completely changed
in the last 30 years. Now, human papillomavirus (HPV) is the leading cause of OPC. While patients with viral OPC tend to be younger and have a superior
responses to treatment and better prognoses compared with non-viral-OPC patients, the biological differences between these cancers are not well understood
due to the paucity of genomic data in the viral-OPC population. The underlying genetic drivers of diverse cancer cell phenotypes, or “tumoral heterogeneity,”
affect clinical outcomes but have not been studied in detail.
In this webinar sponsored by 10x Genomics, Joseph Powell discusses how heterogeneous subpopulations of HPV+ head and neck cancer cells drive unique
disease states, cell–cell interactions, and microenvironment dynamics, and have implications for cancer behavior, metastasis, and response to treatment.JOSEPH POWELL, PHD
Associate Professor
Garvan Institute of Medical Research WATCH NOW!
http://www.the-scientist.com/oropharyngeal-cancer-10xTOPICS COVERED- How tumoral heterogeneity in head and neck cancer affects
clinical outcomes - How to study heterogeneous subpopulations of HPV+
cancer cells using single-cell and spatial techniques
ORIGINALLY AIRED
TUESDAY, SEPTEMBER 8, 2020ONDEMAND
Genetic and Spatial Heterogeneity in Human Papillomavirus-
Associated Oropharyngeal CancerWEBINAR SPONSORED BY
The body’s first line of defense against cancer is the immune system. Yet many tumors evade the immune system and even recruit key immune cells to aid in
tumor development. In this webinar, brought to you by The Scientist and sponsored by 10x Genomics and Codex DNA, Chuanhui Han discusses how cancer
avoids immune system attack after radiation treatment, and Vineet Gupta explores how cancer tricks immune myeloid cells into promoting tumor growth.
The speakers also review therapeutic approaches for preventing cancer’s manipulation of the immune system.CHUANHUI HAN, PHD
Postdoctoral Researcher
Laboratory of Yang-Xin Fu, MD, PhD
UT Southwestern Medical CenterVINEET GUPTA, PHD
The Charles Arthur Weaver Chair of Cancer Research
Vice Chair for Innovation, Department of Internal Medicine
Director, Drug Discovery Center
Rush University Medical CenterWATCH NOW!
http://www.the-scientist.com
/cancer-evades-the-immune-systemTOPICS COVERED- Caspases: The mystery of radiation
- Integrin activation as a novel therapeutic strategy
against cancer
ORIGINALLY AIRED
WEDNESDAY, SEPTEMBER 16, 2020ONDEMAND How Cancer Evades the Immune System
WEBINAR SPONSORED BY